The Claim
In non-obese adults with type 2 diabetes, 12 weeks of daily ipragliflozin 50 mg is associated with a significant reduction in leptin levels without changes in adiponectin or IL-6.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In non-obese adults with type 2 diabetes, taking ipragliflozin 50 mg daily for 12 weeks lowers leptin levels but does not change adiponectin or IL-6 levels.
See the scientific wording
In non-obese adults with type 2 diabetes, 12 weeks of ipragliflozin 50 mg daily is associated with a significant reduction in leptin levels without changes in adiponectin or IL-6, suggesting a selective effect on adipokine regulation.
Blocking glucose reabsorption in the kidneys causes the body to lose sugar in urine, which lowers blood sugar and insulin levels. With less insulin, fat cells stop storing fat and start breaking it down, especially in deep abdominal and heart-area fat. This fat loss specifically reduces the hormone leptin, which is made by fat cells, without affecting other fat-related signals like adiponectin or IL-6.
What the research says
1 studyIn people with type 2 diabetes who aren’t overweight, taking this drug for 12 weeks lowered leptin (a fat-storage hormone) without changing two other fat-related signals, adiponectin and IL-6 — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.